Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genetic Tech Spn Ads (GENE)

Genetic Tech Spn Ads (GENE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,773
  • Shares Outstanding, K 8,523
  • Annual Sales, $ 20 K
  • Annual Income, $ -4,600 K
  • 60-Month Beta 2.54
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.70

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.97 +17.77%
on 06/11/20
2.54 -8.66%
on 06/30/20
+0.22 (+10.48%)
since 06/01/20
3-Month
1.45 +60.00%
on 04/03/20
2.84 -18.31%
on 04/17/20
+0.69 (+42.33%)
since 04/01/20
52-Week
1.41 +64.74%
on 03/23/20
5.36 -56.72%
on 01/10/20
-0.13 (-5.45%)
since 07/01/19

Most Recent Stories

More News
Genetic Technologies CEO to Participate in Investor Webinar and Q&A Session on June 24, 2020

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") is pleased to announce that its interim-CEO Dr. George Muchnicki will share insight into the Company's...

GENE : 2.32 (+1.75%)
US Patent Office Grants Key Risk Test Patent

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") is pleased to announce the issuance of US Patent No: US 10,683,549, Methods for assessing risk of developing...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $8.0 Million Public Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced public offering...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Pricing of $8.0 Million Public Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has priced a public offering of 4,000,000 ...

GENE : 2.32 (+1.75%)
Genetic Technologies Provides Operational Update - Successful Prototype Polygenic Risk Score for COVID-19 Created

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") provides the following operational updates:

GENE : 2.32 (+1.75%)
Genetic Technologies - Accelerated development of new COVID-19 Polygenic Risk Test for Risk of Developing Life-Threatening Complications

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is to commence accelerating development of a polygenic risk score (PRS) test to predict an individual's risk of developing life-threatening complications...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $1.44 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of its previously announced registered direct...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces $1.44 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced that it has entered into definitive agreements with...

GENE : 2.32 (+1.75%)
COVID-19 Testing Capacity at Genetic Technologies Accredited Laboratory

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company") has developed a detailed implementation plan to enable a temporary transition of our genetic testing laboratory to a high-throughput...

GENE : 2.32 (+1.75%)
Genetic Technologies Announces Closing of $1.8 Million Registered Direct Offering

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) (the "Company"), a leader in the development of genetic risk assessment tests, today announced the closing of the previously announced registered direct...

GENE : 2.32 (+1.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade GENE with:

Business Summary

Genetic Technologies was the first company in the world to recognize important new applications for `non-coding` DNA (DeoxyriboNucleic Acid). The Company has since been granted patents securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across...

See More

Key Turning Points

2nd Resistance Point 2.47
1st Resistance Point 2.40
Last Price 2.32
1st Support Level 2.25
2nd Support Level 2.17

See More

52-Week High 5.36
Fibonacci 61.8% 3.85
Fibonacci 50% 3.38
Fibonacci 38.2% 2.92
Last Price 2.32
52-Week Low 1.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar